Amal A. Jouda

Zagazig University, Egypt

Title: HCC after DAA the challenge and the risk

Abstract

Before the national HCV treatment campaign started there were studies that raised concerns about the role of DAA in patients with advanced liver disease and in patients with previous ablation of HCC in enhancing carcinogensis. The health authorities choose to proceed despite those concerns because those patients do not have an alternative therapy to help them achieve viral clearance. Moreover, viral clearance will not only stop further deterioration of their liver disease, but will also prevent the spread of the disease in the society. Wider scale studies were published after the initiation of the campaign based on data from the Egyptian patients and most of them were in favor of the use of DAA in those patients. The studies also emphasized on understanding each patient’s individual risk factors of hepatic carcinogenesis and that patients at higher risk should be referred to tighter follow up schedules to detect focal lesions as soon as they become visible.

Biography

Amal A. Jouda has completed her Msc at the age of 27 years and the MD at the age of 33 years from Zagazig University, Egypt. She is an assistant professor of Tropical Medicine in the Faculty of Medicine, Zagazig University. She is also a first consultant of gastroenterology and Hepatology in Zagazig University Hospitals. She has 20 publications in the fields of hepatology, gastroeneterology and infectious diseases and her publication h-index is 3.

4th International Conference on Oncology Research and Treatment

Amal A. Jouda

Title: HCC after DAA the challenge and the risk

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at